menu
    • menu
    [{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"MR13A9","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Allay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Maruishi Pharmaceutical","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"DA-9501","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase III","graph3":"Maruishi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Maruishi Pharmaceutical \/ Maruishi Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Maruishi Pharmaceutical

    Menu

    Maruishi Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase II

                            Recipient : Allay Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultr...

                            Details : Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : Bupivacaine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase II

                            Recipient : Allay Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin Acetate

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : CARA Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus ...

                            Details : Korsuva (difelikefalin) injection is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus in hemodialysis patients.

                            Product Name : Korsuva

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            September 25, 2023

                            Lead Product(s) : Difelikefalin Acetate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : CARA Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MR13A9

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

                            Details : MR13A9 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pruritus.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 14, 2019

                            Lead Product(s) : MR13A9

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit

                            Details : Dexmedetomidine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 02, 2016

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery With Epidu...

                            Details : Dexmedetomidine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 22, 2011

                            Lead Product(s) : Dexmedetomidine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Maruishi Pharmaceutical

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DA-9501

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical...

                            Details : DA-9501 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 22, 2011

                            Lead Product(s) : DA-9501

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Recipient : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth